Featuring perspectives from Dr Kevin S Hughes and Dr Mark Robson, including the following topics:

• Introduction (0:00)
• Optimal Approach to Genetic Testing for Patients with Localized Breast Cancer (BC) — Dr Hughes (10:22)
• Available Data with and Practical Application of PARP Inhibition as Adjuvant Therapy for Patients with BC — Dr Robson (38:06)

CME information and select publications

Featuring perspectives from Dr Terence Friedlander and Dr Matthew D Galsky, Dr Neeraj Agarwal and Dr Andrew J Armstrong, moderated by Dr Elisabeth I Heath, including the following topics:

• Introduction (0:00)
• Role of Antibody-Drug Conjugates (ADCs) in Front-Line Therapy for Metastatic Urothelial Bladder Cancer (mUBC) — Dr Friedlander (2:53)
• Evidence-Based Use of ADCs for Relapsed/Refractory mUBC — Dr Galsky (33:04)
• Evolving Role of Treatment Intensification with Androgen Receptor Pathway Inhibitors for Nonmetastatic and Metastatic Prostate Cancer — Dr Armstrong (1:01:28)
• Optimal Integration of PARP Inhibitors into Therapy for Prostate Cancer — Dr Agarwal (1:27:49)

CME information and select publications

Featuring an interview with Dr Komal Jhaveri, including the following topics:

• Imlunestrant, an oral selective estrogen receptor degrader (SERD), with and without abemaciclib for ER-positive, HER2-negative advanced or metastatic breast cancer (0:00)
  • Jhaveri KL et al. Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy & combined with abemaciclib, for patients with ER+, HER2- advanced breast cancer (ABC), pretreated with endocrine therapy (ET): Results of the phase 3 EMBER-3 trial. San Antonio Breast Cancer Symposium 2024;Abstract GS1-01.
  • Jhaveri KL et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med 2024;[Online ahead of print]. Abstract
  • Rugo HS et al. Elacestrant abemaciclib (abema) combination in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced or metastatic breast cancer (mBC). San Antonio Breast Cancer Symposium 2024; Abstract PS7-07.
• Elacestrant for ER-positive, HER2-negative metastatic breast cancer with ESR1-mutated tumors: Subgroup analyses from the Phase III EMERALD trial by duration of prior endocrine therapy with a CDK4/6 inhibitor and in clinical subgroups (7:40)
  • Bardia A et al. Elacestrant in ER+, HER2- MBC with ESR1-mutated tumors: Subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups. Clin Cancer Res 2024;30(19):4299-309. Abstract
• Pharmacokinetics and safety of imlunestrant in patients with hepatic impairment (11:25)
  • Wang XA et al. Evaluation of pharmacokinetics and safety of imlunestrant in participants with hepatic impairment. San Antonio Breast Cancer Symposium 2024;Abstract P4-10-07.
• Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer (13:15)
  • Lloyd MR et al. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer. Nat Rev Clin Oncol 2024;21(10):743-61. Abstract

CME information and select publications

Featuring perspectives from Prof John Bridgewater, including the following topics:

• Introduction: Biology and Epidemiology; Classification (0:00)
• Localized Biliary Tract Cancers (6:25)
• First-Line Treatment of Metastatic BTC (20:04)
• HER2-Positive Advanced BTC (24:22)
• Management of Mixed Hepatocellular Carcinoma/BTC Tumors (43:18)
• Advanced Cholangiocarcinoma with an FGFR2 Fusion (47:59)
• Other Important Issues in BTC (52:33)

CME information and select publications

Featuring slide presentations and related discussion from Prof Martin Hutchings, Dr Manali Kamdar, Dr Matthew Lunning and Prof Gilles Salles, including the following topics:

• Evolving Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Kamdar (0:00)
• Case: A 61-year-old man with Stage IV non-GCB DLBCL receives R-CHOP but experiences disease progression 8 months later (30:39)
• Case: A 68-year-old man with double-hit DLBCL who experiences disease progression on chemotherapy and second-line CAR T-cell therapy receives glofitamab (39:22)
• Incorporation of Bispecific Antibody Therapy into DLBCL Management — Prof Hutchings (45:25)
• Case: A 42-year-old man with progressive DLBCL refractory to 2 lines of therapy receives glofitamab with a durable response (1:07:30)
• Case: An 81-year-old woman with multiregimen-refractory DLBCL experiences a prolonged response to epcoritamab (1:14:25)
• Case: A 69-year-old man with follicular lymphoma transformed to DLBCL and refractory to 3 lines of treatment receives glofitamab (1:21:48)
• Selection and Sequencing of Other Available Therapies for Relapsed/Refractory (R/R) DLBCL — Prof Salles (1:24:37)
• Case: An 82-year-old woman with follicular lymphoma transformed to DLBCL receives tafasitamab/lenalidomide (1:42:05)
• Case: A 69-year-old man with urinary bladder carcinoma and recurrent GCB DLBCL receives loncastuximab tesirine (1:46:26)
• Promising Investigational Approaches for Patients with R/R DLBCL — Dr Lunning (2:00:37)
• Case: An 80-year-old woman with multiregimen-refractory GCB DLBCL seeks treatment requiring minimal clinic visits and receives loncastuximab tesirine (2:15:59)
• Case: A 54-year-old man with primary refractory non-GCB DLBCL receives CAR T-cell therapy, and follow-up imaging on day 29 demonstrates a Deauville score of 4 (2:25:22)

CME information and select publications

Featuring perspectives from Dr Arvind Dasari, Dr Christopher Lieu, Dr Van K Morris, Dr Jenny Seligmann and Prof Eric Van Cutsem, moderated by Dr Lieu, including the following topics:

• Introduction (0:00)
• Optimizing Biomarker Assessment for Patients with Colorectal Cancer (CRC) — Dr Dasari (2:18)
• Identification and Management of Metastatic CRC (mCRC) with a BRAF V600E Mutation — Dr Morris (26:37)
• Incorporation of Immune Checkpoint Inhibitors into the Management of Microsatellite Instability-High/Mismatch Repair-Deficient CRC — Dr Seligmann (49:46)
• Integration of Therapies Targeting HER2 into the Management of mCRC — Prof Van Cutsem (1:14:19)
• Biomarker-Based Decision-Making for Patients with mCRC and KRAS G12C Mutations — Dr Lieu (1:36:36)

CME information and select publications

Featuring an interview with Dr Surbhi Sidana, including the following topics:

• Long-term outcomes for patients with relapsed/refractory multiple myeloma (MM) (0:00)
• Clinical considerations in the selection of patients for chimeric antigen receptor (CAR) T-cell therapy (3:34)
• Practical challenges for patients receiving CAR T-cell therapy (8:34)
• Selection among available CAR T-cell therapies (12:18)
• Prevention, management and supportive care involved in the management of toxicities associated with CAR T-cell therapy (16:34)
• Secondary cancers associated with CAR T-cell therapy (21:25)
• Bridging therapy considerations for patients receiving CAR T-cell treatment (25:15)
• Utility of antibody-drug conjugates and bispecific antibodies for MM (27:49)
• Case: A man in his early 40s experiences rapid progression on induction therapy for MM (31:59)
• Case: A man in his early 50s with heavily pretreated MM receives multiple CAR T-cell therapies (41:47)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Surbhi Sidana, including the following topics:

• Key clinical data of FDA-approved chimeric antigen receptor (CAR) T-cell therapies (0:00)
• Real-world evidence evaluating utility of CAR T-cell therapies in the clinic (8:08)
• Impact of prior BCMA-targeted treatment on CAR T-cell therapy efficacy (12:55)
• Investigational CAR T-cell therapies in clinical development (15:08)
• Incidence and management of toxicities associated with CAR T-cell therapy (18:21)

CME information and select publications